Prognostic significance of angiogenesis in human pancreatic cancer by Ikeda, N et al.
Pancreatic cancer can entail the substantial development of new
blood vessels within the tumour tissue, and it is known that the
growth and progression of solid tumours depend on such angio-
genesis (Folkman, 1995a). Angiogenesis is an integral part of
the cascade of biologic events involved in tumour metastasis
(McCulloch et al, 1995). The mechanisms by which neovascular-
ization stimulates tumour progression are the delivery of the
nutrients and oxygen necessary for tumour cell growth, the facili-
tation of the penetration of tumour cells through the vessel walls
and their transport to distant organs, and the secretion of selective
cytokines and growth factors from endothelial cells that directly
stimulate tumour cells (Fidler and Ellis, 1994). The conversion of
tumour cells to an angiogenic phenotype may be preceded by a
change in the balance of angiogenic growth factors and angio-
genesis inhibitors. To date, many angiogenic factors for pancreatic
cancers have been reported, such as transforming growth factor-a
(TGF-a) (Barton et al, 1991), transforming growth factor-b
(TGF-b) (Friess et al, 1993), acidic fibroblast growth factor
(aFGF), basic fibroblast growth factor (bFGF) (Yamanaka et al,
1993), angiogenin (Shimoyama et al, 1996), vascular endothelial
growth factor (VEGF) (Itakura et al, 1997) and platelet-derived
endothelial cell growth factor (PD-ECGF) (Minari et al, 1997).
However, since angiogenesis is composed of multistep processes
controlled by various factors, the role of angiogenesis in pancreatic
cancer has not been fully elucidated. This study was conducted to
determine whether the levels of PD-ECGF and VEGF gene
expression measured in primary tumours from patients with
pancreatic cancers were associated with known prognostic factors
and patient survival. Furthermore, to clarify whether PD-ECGF
and VEGF correlate with tumour angiogenesis, we examined the
intratumoral microvessel density (IMD) by immunohistochemical
analysis using anti-CD34 monoclonal antibodies.
MATERIALS AND METHODS
Cell lines and tumour tissues
Four human pancreatic cancer cell lines (Capan-2, HPAF-II, PANC-
1 and MIA PaCa-2) were maintained in DMEM supplemented with
10% fetal calf serum. Forty patients with pancreatic cancers under-
went surgery at the First Department of Surgery, Nara Medical
University, between December 1992 and September 1997. The
median age of the patients was 63 years, with a range of 47–80
years. When distant metastasis was solitary and resectable, pancrea-
tectomy was performed. Thus, six patients with distant metastasis
underwent surgery. Following pancreatectomy, all patients received
intraoperative radiation therapy (IORT) with 20 gray (Gy) of elec-
tron beam on the retroperitoneal field, including the origins of the
portal vein, celiac and superior mesenteric arteries. Moreover,
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Summary To evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral
microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also
investigated PD-ECGF and VEGF gene expression using reverse transcriptase-PCR (RT-PCR). Of the 40 pancreatic cancers studied, 30
carcinomas (75.0%) were evaluated to be PD-ECGF-positive and 10 carcinomas (25.0%) were determined to be PD-ECGF-negative. In
contrast, 27 carcinomas (67.5%) were evaluated to be VEGF-positive, whereas 13 carcinomas (32.5%) were VEGF-negative. VEGF gene
expression was moderately associated with an increase in the IMD (r 2 = 0.181, P = 0.006), but no significant relationship was found between
PD-ECGF gene expression and the IMD (r 2 = 0.093, P = 0.059). However, tumours with positive expression for both PD-ECGF and VEGF
had a higher IMD (P = 0.027). The results of the immunohistochemistry agreed well with the results of the quantitative RT-PCR. The median
survival time of the hypervascular group was significantly shorter than that of the hypovascular group (P < 0.0001). In comparing the survival
according to PD-ECGF and VEGF gene expression, the median survival time of the patients with positive PD-ECGF expression was
significantly shorter than those with negative PD-ECGF expression (P = 0.040). Furthermore, the median survival time of the patients with
positive VEGF expression was significantly shorter than those with negative VEGF expression (P = 0.048). However, the Cox multivariate
analysis indicated that the IMD and VEGF expression were independent prognostic factors of the various clinicopathologic variables in
pancreatic cancer patients (P = 0.0021 and P = 0.0443, respectively).
Keywords: PD-ECGF; VEGF; pancreatic cancer; prognosis and intratumoral microvessel density (IMD)
1553
British Journal of Cancer (1999) 79(9/10), 1553–1563
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0248
Received 14 April 1998
Revised 4 September 1998
Accepted 29 September 1998
Correspondence to: M Miyake6 mg/m2 mitomycin C and 500 mg/m2 5-fluorouracil were adminis-
tered into the portal vein. Post-operative systemic chemotherapy
was not given before recurrence.
All of the tissues were obtained from resected specimens,
and then were quickly stored at –80°C until used. The residual
specimens were fixed in 10% phosphate buffered formalin and
embedded in paraffin. In order to ascertain the presence of cancer
cells, one half of each fresh tumour tissue specimen was immedi-
ately embedded in optimum cutting temperature (OCT)-compound
(Miles, Kankakee, IL, USA), and frozen sections were then cut on
the cryostat to a thickness of 6 mm and immediately we reviewed
the H&E-stained slides of the tumour specimens. After the
connective tissues were trimmed off, the other half of the tumour
specimen containing greater than 80% cancer cells of all tissue
cells was selected for the RT-PCR analysis. The tumours were
classified according to the tumour–node–metastasis (TNM) staging
system (Sobin and Wittekind, 1997). The clinical characteristics of
these patients are presented in Table 1. The median follow-up for
all patients was 25.9 months, with a range of 5–62 months.
RT-PCR analysis
The total cellular RNA was extracted from the cell lines and frozen
tumour tissues by the acid guanidinium thiocyanate procedure
(Chomczynski and Sacchi, 1987). In a preliminary study, we
confirmed that the human colon cancer cell line colo 201 had PD-
ECGF and VEGF mRNA expression as a positive control. First-
strand cDNA synthesis was performed with 5 mg of total RNA,
using a cDNA synthesis kit (Pharmacia, Piscataway, NJ, USA) and
following the manufacturer’s protocol. For PCR amplification, we
used a 1-ml aliquot of the reaction mixture. To obtain reproducible
quantitative performance of RT-PCR assays for PD-ECGF and
VEGF, we titrated the amount of starting cDNA against the
number of amplification cycles. The generated cDNAs were
amplified using primers for PD-ECGF (5¢-CTGATCCGCAT-
GAAGCGAGAC-3¢ and 5¢-CTCCACGAGTTTCTTACTGAGA-
AT-3¢) (Ishikawa et al, 1989), VEGF (5¢-GAAGTGGTGAAGTT-
CATGGATGTC-3¢ and 5¢-CGATCGTTCTGTATCAGTCTTTCC-
3¢) (Tischer et al, 1991), and b-actin (5¢-GAGAGATGACCCA-
GATCATGT-3¢ and 5¢-ACTCCATGCCCAGG AAGGAAGG-3¢)
(Nakajima-Iijima et al, 1985). All subsequent assays were carried
out using those parameters that yielded an amplification of both
PD-ECGF, VEGF and b-actin (the internal control) within a linear
range. The PD-ECGF and VEGF reaction mixture was subjected
to 28 PCR amplification cycles of 40 s, each at 94°C, 40 s at 60°C,
and 90 s at 72°C. The same PCR conditions of 20 cycles were used
to amplify the b-actin DNA. Tubes containing all of the ingredients
except for the templates were included in all runs, and served
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Table 1 Relationship between PD-ECGF or VEGF gene expression, the IMD and known prognostic factors
PD-ECGF VEGF IMD
Characteristics Total (n) (+) (–) P-value (+) (–) P-value (+) (–) P-value
Age at surgery
≤ 60 27 23 4 NSa,b 19 8 NSa,b 12 15 NSa,b
> 60 13 7 6 8 5 7 6
Gender
Male 30 22 8 NSa,b 19 11 NSa,b 12 18 NSa,b
Female 10 8 2 8 2 7 3
Tumour status
T1 4 1 3 0.0353c 22 N S a,b 1 3 0.0248c
T2 2 1 1 2 0 0 2
T3 9 6 3 6 3 8 1
T4 25 22 3 17 8 10 15
Nodal status
N0 20 14 6 NSa,b 12 8 NSa,b 81 2 N S a,b
N1 20 16 4 15 5 11 9
Metastatic status
M0 34 25 9 NSa,b 22 12 NSa,b 15 19 NSa,b
M1 6 5 1 5 1 4 2
Pathological stage
Stage I 5 1 4 0.0350c 32 N S a,c 14 N S a,c
Stage II 4 3 1 3 1 4 0
Stage III 5 3 2 3 2 3 2
Stage IVa 20 18 2 13 7 7 13
Stage IVb 6 5 1 5 1 4 2
Histopathological
grading
G 1 14 8 6 0.0374c 5 9 0.0058c 4 10 0.0423c
G 2 21 17 4 18 3 11 10
G 3 5 5 0 4 1 4 1
Total number  40 30 10 27 13 19 21
of patients
aNS, not significant. bc2 test. cMann–Whitney’s U-test.as negative reaction controls. The amplified DNA samples were
run on a 1% agarose gel, and the bands were visualized with
ethidium bromide and photographed with a Polaroid camera.
Densitometric analysis of the photographic negatives was used for
band quantification.
Specimen classification based on RT-PCR results
The densitometric values obtained for the PD-ECGF and VEGF
bands in a given tumour tissue sample were divided by the corre-
sponding value for b-actin, and the ratio was referred to as the
gene expression ratio for each gene. VEGF has four isoforms
(121, 165, 189 and 206 amino acids), resulting from the alterna-
tive splicing of the primary transcript (Tischer et al, 1991); there-
fore, we divided the value obtained for VEGF121 by the
corresponding value for b-actin. The expression ratio in a given
tumour was then divided by the expression ratio of the human
colon cancer cell line colo 201 in order to obtain the gene conser-
vation rates for PD-ECGF and VEGF. Since most prognostic
factors are usually considered as dichotomized, discontinuous
variables, a cut-off point was selected to give the optimal separa-
tion between a low and high risk of the overall survival as
described previously (Tandon et al, 1990). Thus, the most signifi-
cant P-value for the survival was found by a relative cut-off point
for positive PD-ECGF expression of 1.5. When the conservation
rate value of a given specimen was > 1.5, it was considered
to indicate positive PD-ECGF gene expression. If the value was
≤ 1.5, it was considered to represent negative expression. This
was true of a relative cut-off point for positive VEGF expression
of 1.0. When the conservation rate value of a given specimen was
> 1.0, it was considered to indicate positive VEGF gene expres-
sion, whereas a ratio ≤ 1.0 was considered to represent negative
expression.
Immunohistochemical staining of PD-ECGF, VEGF
and CD34
We used a mouse monoclonal antibody obtained from Nippon
Roche Research Center at a 1:100 dilution for PD-ECGF, a rabbit
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) at a 1:200 dilution for VEGF, and a mouse monoclonal anti-
body (Nichirei Corporation, Tokyo, Japan) at a 1:20 dilution for
CD34. After the sections were incubated with normal goat serum
to block the non-specific binding, they were treated with the anti-
PD-ECGF, anti-CD34 or anti-VEGF antibodies at room tempera-
ture. Immunostaining was performed by the streptavidin-biotin
(SAB)s method using Histofine SAB-PO (M) and SAB-PO (R)
kits (Nichirei, Tokyo, Japan). The staining was visualized with
3,3¢-diaminobenzidine tetrahydrochloride. The slides were coun-
terstained with haematoxylin. Sections incubated with mouse
myeloma SP2 supernatant or normal rabbit IgG served as negative
reaction controls.
Evaluation of immunostaining and microvessel counting
At least 200 tumour cells were scored per 400 ´ field. Positive
tumour cells were stained to an intensity equivalent to normal
fibroblasts. When > 10% of the carcinoma cells in a given speci-
men were positively stained, the sample was classified as PD-
ECGF-positive (+) or VEGF-positive (+), and when ≤ 10% of the
cells were stained, the sample was designated as negative (–). For
the microvessel counting, the four most highly vascularized areas
were counted in 200 ´ fields (0.785 mm2 per field), and the
average counts were recorded. The mean microvessel count of
these tumours was 58.6 ± 17.4. Therefore, we classified the
tumours into two groups: tumours with a microvessel count >58.6
were classified as hypervascular, and tumours with a count ≤ 58.6
were classified as hypovascular. The evaluation of PD-ECGF
and VEGF staining and the microvessel counting were performed
by two investigators who had no knowledge of the patients’
clinicopathologic factors or clinical outcomes.
Statistical analysis
The overall cancer-specific survival was defined from the date of
the operation to the data of death due to cancer. The statistical
significance of the difference between the incidence of PD-ECGF
or VEGF gene expression and several clinical and pathological
parameters was assessed by the c2 test or by Mann–Whitney’s
U-test. Pearson’s correlation coefficient was performed to examine
correlation between PD-ECGF or VEGF gene expression and the
IMD. The Kaplan–Meier method was used to estimate the proba-
bility of overall survival as a function of time (Kaplan and Meier,
1958) and was compared using the log-rank test (Mantel, 1966).
Multivariate analysis were performed by using the Cox regression
model (Cox 1972) with the SAS statistical package (SAS Institute,
Cary, NC, USA), and nine factors (PD-ECGF status, VEGF
status, intratumoral microvessel density (IMD), histopathological
grading, tumour status, nodal status, metastatic status, gender and
age at surgery) were studied; scores were also assigned to each
variable for the regression analysis. All P-values were based on a
two-tailed statistical analysis and a P < 0.05 was considered to
indicate statistical significance.
RESULTS
PD-ECGF and VEGF gene expression in pancreatic
cancer cell lines and tumour tissues analysed by
RT-PCR
PD-ECGF mRNA was detected in three (75.0%) of the four
human pancreatic cancer cell lines by the RT-PCR assay; only the
MIA PaCa-2 cell line had no PD-ECGF gene expression (Figure
1A). Of the 40 pancreatic cancers studied, 30 carcinomas (75.0%)
were evaluated to be PD-ECGF-positive, and 10 carcinomas
(25.0%) were determined to be PD-ECGF-negative (Figure 1A).
The PD-ECGF gene expression rate ranged from 0 to 6.34, with a
mean value of 2.71. In contrast, all four human pancreatic cancer
cell lines had VEGF mRNA expression (Figure 1B). Twenty-seven
carcinomas (67.5%) were evaluated to be VEGF-positive, and 13
carcinomas (32.5%) were VEGF-negative (Figure 1B). The VEGF
gene expression rate ranged from 0 to 3.24, with a mean value of
1.43. There was no significant correlation between the gene
expression ratios of PD-ECGF and VEGF (r2= 0.025).
PD-ECGF and VEGF protein expression analysed by
immunohistochemistry
The PD-ECGF protein positive ratio obtained by immunohisto-
chemistry was 67.5% (27 out of 40). PD-ECGF protein was found
mainly in the cytoplasm and nuclei of the cancer cells. In addition,
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2A). The PD-ECGF gene expression evaluated by the RT-PCR
was highly associated with PD-ECGF protein expression by the
immunohistochemical staining (r2 = 0.51, P < 0.0001) (Figure
3A). Overall, the results of the PD-ECGF immunohistochemistry
agreed well with the RT-PCR assay data, and 90.0% of the samples
coincided exactly. On the other hand, the VEGF protein positive
ratio was 60.0% (24 out of 40). VEGF protein was found mainly in
the cytoplasm and islets. Occasionally, the nuclei of the cancer and
stromal cells, which may have been macrophages or fibroblasts,
were also stained (Figure 2B). The VEGF gene expression evaluated
by the RT-PCR was also associated with VEGF protein expression
by the immunohistochemical staining (r2 = 0.52,  P < 0.0001)
(Figure 3B). These results also agreed well with the RT-PCR assay
data, and 92.5% of the samples coincided exactly. In the case of a
discrepancy, the results from the RT-PCR analysis were used in the
specimen classification.
Microvessel staining
A single microvessel was defined as any brown immunostained
endothelial cells separated from the adjacent microvessels, tumour
cells, and other connective tissue elements (Figure 2C). The
microvessel count for the 40 tumours ranged from 33.0 to 117.0,
with a mean microvessel count of 58.6 ± 17.4. The 40 patients
were then classified into two groups: 19 patients with hyper-
vascular tumours and 21 patients with hypovascular tumours.
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Figure 2 Immunohistochemical staining for PD-ECGF (A). The PD-ECGF
antigen was found mainly in the cytoplasm and nuclei of cancer cells. In
addition, the islets and stromal cells, which may be macrophages or
fibroblasts, were also stained. Immunohistochemical staining for VEGF (B).
The VEGF antigen was found mainly in the cytoplasm and nuclei of cancer
cells. Occasionally, the nuclei of cancer and stromal cells, which may be
macrophages or fibroblasts, were also stained. Immunohistochemical
staining for microvessel (C). A single microvessel was defined as any brown
immunostained endothelial cell separated from the adjacent microvessels,
tumour cells, and other connective tissue elements. A and B: original
magnification ´ 100. Bars = 20 mm. C: original magnification ´ 200.
Bars = 10 mm
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Figure 1 Agarose gel electrophoresis of RT-PCR amplified PD-ECGF
cDNA (A). Lane 1, size marker; lane 2, human colon cancer cell line colo 201
(positive control); lanes 3–4, primary pancreatic adenocarcinomas evaluated
as PD-ECGF gene expression positive; lanes 5–6, primary pancreatic
adenocarcinomas evaluated as PD-ECGF gene expression negative; lanes
7–10, human pancreatic cancer cell lines (Capan-2, HPAF-II, PANC-1 and
MIA PaCa-2). Agarose gel electrophoresis of RT-PCR amplified VEGF cDNA
(B). Lane 1, size marker; lane 2, human colon cancer cell line colo 201
(positive control); lanes 3–4, primary pancreatic adenocarcinomas evaluated
as VEGF gene expression positive; lanes 5–6, primary pancreatic
adenocarcinomas evaluated as VEGF gene expression negative; lanes
7–10, human pancreatic cancer cell lines (Capan-2, HPAF-II, PANC-1 and
MIA PaCa-2). Agarose gel electrophoresis of RT-PCR amplified b-actin
cDNA (C)Relationships between PD-ECGF or VEGF gene
expression and the IMD
No significant relationship was found between the expression ratio
of PD-ECGF and the IMD (Figure 4A; r2 = 0.093, P = 0.059), but
the expression ratio of VEGF was moderately associated with an
increase in the IMD (Figure 4B; r2 = 0.181, P= 0.006).
Relationship between PD-ECGF or VEGF gene
expression, the IMD and known prognostic factors
The relationship between PD-ECGF gene expression and various
prognostic factors is shown in Table 1. PD-ECGF gene expression
was associated with the histopathological grading (P = 0.0374),
the tumour status (P = 0.0353), and the pathological stage
(P = 0.0350). 100% of the G3 grade patients had positive gene
expression, as compared with 57.1% of the G1 grade patients.
With respect to the tumour status, the proportion of patients whose
tumours had positive gene expression increased from 25.0% of
those with a T1 status to 88.0% of those patients with a T4 status.
In addition, 83.3% of the Stage IVb patients had positive gene
expression compared with 22.0% of the Stage I patients. In
contrast, there was no significant relationship between PD-ECGF
gene expression and the patients’ age at surgery, gender, nodal
status or metastatic status.
The relationship between VEGF gene expression and various
prognostic factors is shown in Table 1. VEGF gene expression was
also significantly associated with the histopathological grading
(P = 0.0058); 80.0% of the G3 grade patients had positive gene
expression as compared with 35.7% of the G1 grade patients. In
contrast, there was no statistically significant relationship between
VEGF gene expression and the other factors.
The IMD was significantly associated with the histopatholog-
ical grading (P = 0.0423) and tumour status (P = 0.0248); 80.0% of
the G3 grade patients were classified to the hypervascular group,
as compared with 28.6% of the G1 grade patients. With respect to
the tumour status, the proportion of patients with hypervascular
tumours increased from 25.0% of those with a T1 status to 40.0%
of those patients with a T4 status. There was no statistically signif-
icant relationship between the IMD and the other factors.
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Figure 3 Pearson’s correlation coefficient between gene conservation rate
by RT-PCR and protein expression by immunohistochemistry. The
association between PD-ECGF gene expression and PD-ECGF protein
expression (A). The association between VEGF gene expression and VEGF
protein expression (B)
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Figure 4 There was no significant correlation between the expression ratio
of PD-ECGF and the IMD (A). However, the expression ratio of VEGF was
moderately associated with an increase in the intratumoral microvessel
density (IMD) (B)Association of PD-ECGF and VEGF gene expression
and the IMD with the survival of pancreatic cancer
patients
The prognosis of patients with pancreatic cancer was very poor,
and the overall survival rates for almost all of the factors were 0%.
Of the 40 patients with pancreatic cancer, the median survival time
of the patients with positive PD-ECGF gene expression was
shorter than that of the patients with negative PD-ECGF gene
expression, as demonstrated in Table 2 (9.5 months vs not reached,
P = 0.040; Figure 5A). This difference was particularly evident in
those patients with a M0 metastatic status (11.3 months vs not
reached; P = 0.035). Furthermore, there was a medical significant
difference in N0 nodal status (14.0 months vs not reached; P =
0.041). The median survival time of the patients with positive
VEGF expression was lower than that of the patients with negative
VEGF expression, as demonstrated in Table 3 (7.5 months vs 14.0
months; P = 0.048; Figure 5B). This difference was particularly
evident in male and elderly patients (P = 0.027 and P = 0.039,
respectively).
On the other hand, the median survival time of the hyper-
vascular group was shorter than that of the hypovascular group in
Table 4 (6.3 months vs 18.8 months; P < 0.0001; Figure 5C). In
addition, there were significant differences noted for the following
variables: male (6.3 months vs 21.6 months; P < 0.0001), elderly
patients (6.3 months vs 18.8 months; P = 0.0035), T4 tumour
status (7.5 months vs 14.0 months; P = 0.0004), N0 or N1 nodal
status (4.7 months vs 27.6 months; P = 0.0087 and 6.8 months vs
13.2 months; P = 0.0038), M0 metastatic status (6.3 months vs
21.6 months; P < 0.0001), Stage IVa (6.1 months vs 18.8 months;
P < 0.0001) and G1 or G2 histopathological grading (6.8 months
vs 14 months; P = 0.0027 and 6.1 months vs 21.6 months;
P = 0.0070).
Prognostic value of PD-ECGF status, VEGF status, and
IMD
We studied the independent prognostic value of each variable used
in the Cox regression analysis as shown in Table 5. The IMD and
VEGF status were found to be significant independent prognostic
factors (P = 0.0021 and P = 0.0443, respectively). The other vari-
ables (PD-ECGF status, histopathological grading, tumour status,
nodal status, metastatic status, gender, age at surgery) were not
significant.
DISCUSSION
Tumour growth depends on angiogenesis to a large degree, which
means that the tumours are dependent on the ingrowth of a
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Table 2 Association of PD-ECGF gene expression with the survival of pancreatic cancer patients
Median survival Overall survival
time (month) rate (%)
PD-ECGF PD-ECGF
Characteristics Total (n) (+) (–) (+) (–) P-value
Age at surgery (yr)
≤ 60 27 7.8 6.8 0 50 0.287
> 60 13 10.6 NRa 0 75 0.090
Gender
Male 30 8.7 NRa 0 57.1 0.104
Female 10 10.6 NRa 0 100 NDb
Tumour status
T1 4 NRa NRa 100 100 NDb
T2 2 11.3 NRa 0 100 NDb
T3 9 4.9 6.3 0 0 0.702
T4 25 9.5 NRa 0 66.7 0.594
Nodal status
N0 20 14.0 NRa 0 80 0.041
N1 20 8.7 6.8 0 33.3 0.702
Metastatic status
M0 34 11.3 NRa 0 71.4 0.035
M1 6 6.4 5.0 0 0 0.351
Pathological stage
Stage I 5 NRa NRa 100 100 NDb
Stage II 4 24.3 6.3 0 0 0.515
Stage III 5 11.3 6.8 0 0 0.515
Stage IVa 20 10.6 NRa 0 100 0.351
Stage IVb 6 6.4 5.0 0 0 0.351
Histopathological
grading
G 1 14 9.5 NRa 16.7 75 0.171
G 2 21 10.6 6.3 0 50 0.868
G 3 5 8.3 – 0 – –
Total number of patients 40 9.5 NRa 0 62.5 0.040
aNR, not reached.  bND, not done.vascular supply from the surrounding tissues in order to proliferate
and metastasize (Folkman, 1995a; McCulloch et al, 1995). Any
individual tumour may have dominant angiogenic factors that
favour the imbalance of positive regulators and negative ones
to induce angiogenesis. Of these factors, PD-ECGF and VEGF
are particularly important angiogenic factors. PD-ECGF is an
endothelial cell mitogen of relative molecular mass purified to
homogeneity from human platelets, and has chemotactic activity
for endothelial cells in vitro and angiogenic activity in vivo
(Ishikawa et al, 1989). In 1992, PD-ECGF was identified as being
homologous to thymidine phosphorylase (dThdPase), which catal-
yses the reversible phosphorylation of thymidine to thymine and
2-deoxyribose-1-phosphate (Furukawa et al, 1992; Usuki et al,
1992); this enzymatic activity is crucial for the angiogenic activity.
Takahashi et al (1996) have demonstrated that PD-ECGF was
expressed in infiltrating cells in most of colon cancers, but rarely
in tumour epithelium. However, in our cases three of four pancre-
atic cell lines have PD-ECGF gene expression and the PD-ECGF
protein positive ratio obtained by immunohistochemistry was
67.5% (27 out of 40).
On the other hand, VEGF is a potent and widely distributed
angiogenic peptide (Dvorak et al, 1995). This growth factor is a
dimeric 34–42 kD glycosylated basic protein with moderate
affinity for heparin, and is encoded in four molecular isoforms
(121, 165, 189 and 206 amino acids) resulting from the alternative
splicing of the primary transcript (Tischer et al, 1991). Two
smaller isoforms (VEGF121 and 165) are secretary proteins,
whereas the other two larger isoforms (VEGF189 and 206) are
bound to heparin-containing proteoglycans or the cell surface or
basement membrane (Houck et al, 1992). The former isoforms
induce their angiogenic effects by binding to the specific trans-
membrane tyrosine kinase receptors KDR/flk-1 and flt-1, also
termed VEGFR-1 and VEGFR-2, respectively, which are selec-
tively expressed on vascular endothelial cells (Dvorak et al, 1995).
Aberrant levels of VEGF have also been found in the sera from
10% of the patients with early-stage breast cancer (Yamamoto
et al, 1996). However, the biologic significance of circulating
endothelial growth factors is presently not known. In this study,
since VEGF121 and VEGF165 mRNAs were potently expressed
and high VEGF121 expression was found in the tumours with
elevated vascularization (Houck et al, 1992), we studied the
VEGF121 expression. VEGF expression increases in response to
several stimuli such as hypoxia (Brogi et al, 1996), certain onco-
gene products including mutant ras genes (Rak et al, 1995) and the
overexpression of transforming growth factor (Detmar et al,
1994). In addition to tumour growth and metastasis, the endo-
genous upregulation of VEGF has been implicated as the basis for
the angiogenesis associated with diabetic retinopathy (Aiello et al,
1994), rheumatoid arthritis (Fava et al, 1994), and wound healing
(Tsurumi et al, 1997).
Recently, many studies have suggested that the IMD was a
significant predictor of an increased risk of metastasis and a poorer
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Table 3 Association of VEGF gene expression with the survival of pancreatic cancer patients
Median survival Overall survival
time (month) rate(%)
VEGF VEGF
Characteristics Total (n) (+) (–) (+) (–) P-value
Age at surgery (yr)
≤ 60 27 6.1 8.7 28.6 0 0.564
> 60 13 8.3 NRa 0 51.4 0.039
Gender
Male 30 6.8 14.0 11.8 23.3 0.027
Female 10 10.6 NRa 0 100 NDb
Tumour status
T1 4 NRa NRa 100 100 NDb
T2 2 11.3 – 50.0 – NDb
T3 9 5.0 NRa 0 100 NDb
T4 25 8.3 13.2 0 0 0.246
Nodal status
N0 20 18.8 27.6 18.5 28.6 0.303
N1 20 7.5 13.2 0 0 0.306
Metastatic status
M0 34 10.6 27.6 9.6 25.9 0.086
M1 6 5.0 8.7 0.0 0 0.156
Pathological stage
Stage I 5 NRa NRa 100 100 NDb
Stage II 4 6.3 NRa 0 100 NDb
Stage III 5 6.8 NRa 0 100 NDb
Stage IVa 20 10.6 13.2 0 0 0.365
Stage IVb 6 5.0 8.7 0 0 0.156
Histopathological grading
G1 14 11.3 14.0 33.3 42.9 0.579
G2 21 7.5 27.6 0 0 0.078
G3 5 4.2 8.7 0 0 0.754
Total number of patients 40 7.5 14.0 7.8 23.3 0.048
aNR, not reached. bND, not done.overall survival of solid tumour (Weidner and Folkman, 1996). Our
study also showed that the IMD was the most significant indicator
of a poor prognosis among PD-ECGF expression, VEGF expres-
sion and the IMD. In colon cancers, PD-ECGF has been reported to
be closely related to the IMD (Takebayashi et al, 1996), and in
gastric cancers VEGF was also correlated with the IMD (Takahashi
et al, 1998). However, in pancreatic cancers, no significant relation-
ship was found between PD-ECGF expression and the IMD
(r2 = 0.093, P = 0.059); only VEGF expression was moderately
correlated with the IMD (r2 = 0.181, P = 0.006). These data agreed
well with the previous report by Itakura et al (1997). Indeed,
PD-ECGF gene expression correlated with a poor prognosis in
patients with pancreatic cancer, but these findings suggest that
PD-ECGF may not play a more important role in angiogenesis
than VEGF. However, tumours with both positive PD-ECGF and
VEGF gene expression had a higher IMD than those with either
negative or both negative expression (P = 0.027; c2 test).
Furthermore, these patients with both positive PD-ECGF and
VEGF gene expression had a significantly poorer prognosis than
those with either negative or both negative expression (P = 0.010).
The activity of one factor may therefore facilitate the angiogenic
activity of the other factor. For example, the chemotactic activity of
PD-ECGF might facilitate tubule formation after the proliferation
of the endothelial cells secondary to VEGF activity (Takahashi et
al, 1998). However, apart from PD-ECGF and VEGF, other domi-
nant angiogenic factors that might directly correlate with angio-
genesis in pancreatic cancers should be considered. Furthermore,
the coexpression of diverse endothelial growth factors may have a
synergistic effect on angiogenesis and ultimately, neovasculariza-
tion is probably the result of the net local balance between angio-
genic stimuli and angioinhibitory pathways (Folkman, 1995a;
Hanahan and Folkman, 1996). Therefore, the IMD may provide
prognostic information on the clinical behaviour of pancreatic
cancers.
We found that an assessment of the PD-ECGF and VEGF gene
expression levels by RT-PCR was useful. In general, immuno-
histochemical methods are evaluated by subjective criteria.
Therefore, we believe that the RT-PCR assay we used is a valuable
and objective method of detecting PD-ECGF and VEGF.
However, a histologic control is very important for evaluating
blind RNA analysis, so we initially selected specimens containing
greater than 80% cancer cells of all tissue cells selected for the
RT-PCR analysis and these results were ascertained by immuno-
histochemistry. In addition, the potential advantages of this assay
system are that it can distinguish the different isoforms of VEGF
and that it may lead to the identification of the cellular sources of
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Table 4 Association of IMD with the survival of pancreatic cancer patients
Median survival Overall survival
time (month) rate(%)
IMD IMD
Characteristics Total (n) (+) (–) (+) (–) P-value
Age at surgery (yr)
≤ 60 27 6.1 27.6 0 30 0.0750
> 60 13 6.3 18.8 0 19.7 0.0035
Gender
Male 30 6.3 21.6 0 25.2 < 0.0001
Female 10 6.1 18.8 0 0 0.4385
Tumour status
T1 4 NRa NRa 100 100 NDb
T2 2 – 11.3 – 50 NDb
T3 9 6.3 NRa 0 100 NDb
T4 25 7.5 14.0 0 0 0.0004
Nodal status
N0 20 4.7 27.6 0 36.6 0.0087
N1 20 6.8 13.2 0 0 0.0038
Metastatic status
M0 34 6.3 21.6 0 25.5 < 0.0001
M1 6 8.3 5.0 0 0 0.3636
Pathological stage
Stage I 5 NRa NRa 100 100 NDb
Stage II 4 6.3–0– N D b
Stage III 5 4.9 11.3 0 0 0.0900
Stage IVa 20 6.1 18.8 0 0 < 0.0001
Stage IVb 6 8.3 5.0 0 0 0.364
Histopathological grading
G1 14 6.8 14.0 0 44.4 0.0027
G2 21 6.1 21.6 0 0 0.0070
G3 5 4.2 18.8 0 0 0.1564
Total number of patients 40 6.3 18.8 0 22.9 < 0.0001
aNR, not reached. bND, not done.VEGF. In fact, some stromal cells have also been shown to be able
to produce this endothelial growth factor (Yoshiji et al, 1996).
Thus far, the angiogenic properties of pancreatic cancers have
been unclear because pancreatic cancers have been known to be
hypovascular tumours via roentgenographic imaging. In this study,
we demonstrated that angiogenesis depended on VEGF more than
PD-ECGF, and the tumours with both PD-ECGF and VEGF gene
expression had a higher IMD (P = 0.027; c2 test). The results of
our study suggested that VEGF was the main angiogenic pathway
in human pancreatic cancers. Another important clinical implica-
tion of our results, beyond the prognosis, is that VEGF may be a
potentially useful target for the pharmacologic inhibition of angio-
genesis (Folkman, 1995a; Folkman, 1995b). Some investigations
have succeeded in the suppression of tumour growth in vivo
through the inhibition of angiogenesis by blocking the biologic
functions of VEGF. For example, neutralizing antibodies against
VEGF (Kim et al, 1993), cytotoxic conjugates of recombinant
VEGF with diphtheria toxin (Ramakrishnan et al, 1996), and
genetic approaches using retroviruses encoding dominant negative
mutant KDR/flk-1 receptors capable of infecting and inhibiting the
growth of target endothelial cells (Millauer et al, 1994) have all
brought about angiogenesis-related tumour regression in animal
models. Human pancreatic cancer still has a very poor prognosis
even after a curative resection (Nitecki et al, 1995). Only 8% of
the patients are resectable at the time of diagnosis, and the overall
5-year survival rate is less than 10% because most patients die
from recurrent diseases (Bramhall et al, 1995; Gastrointestinal
Tumor Study Group, 1987). Based on the high rate of recurrence,
surgery alone seems to be inadequate for the treatment of patients
with pancreatic cancer. Indeed, new clinical approaches such as,
for example adjuvant chemotherapy plus radiation therapy
(chemoradiation) after surgery or before surgery have been
attempted and only a little improvement was observed in the
survival rates of patients with pancreatic cancer, but the prognosis
has remained worse than other cancers, such as breast cancer,
colon cancer and gastric cancer (Ozaki et al, 1996; Schnall et al,
1996; Kamthan et al, 1997). In addition, most patients with
pancreatic cancers are already unresectable when they are initially
diagnosed. Therefore, the development of angiogenesis inhibitors
poses several challenges to the identification of the optimal study
design, the criteria for eligibility of the patients, the modalities and
schedule of administration, and the criteria for the evaluation of
their biologic and therapeutic efficacy in pancreatic cancer
patients. In any case, at present, the inhibition of angiogenesis
represents one of the most promising novel therapeutic strategies
to improve the management of pancreatic cancer.
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Table 5 Multivariate Cox analysis of overall survival of 40 patients with pancreatic cancer
Variable Assigned score b S.E. c2 Hazard ratio (95% CI) P-value
IMD
Hypervascular 0 – 2.07 0.672 9.499 0.126 (0.034–0.471) 0.0021
Hypovascular 1
PD-ECGF
Positive 0 – 1.11 0.983 1.276 0.329 (0.048–2.262) 0.2586
Negative 1
VEGF
Positive 0 – 1.747 0.868 4.047 0.174 (0.032–0.956) 0.0443
Negative 1
Histopathological grading
G1 1 – 0.856 0.688 1.549 0.425 (0.110–1.636) 0.2133
G2 2
G3 3
Tumour status
T1 1 1.046 0.599 3.052 2.846(0.880–9.200) 0.0806
T2 2
T3 3
T4 4
Nodal status
N0 0 – 0.174 0.607 0.082 0.840 (0.256–2.759) 0.7740
N1 1
Metastatic status
M0 0 0.788 0.865 0.83 2.198 (0.404–11.976) 0.3624
M1 1
Gender
Male 0 1.346 0.732 3.378 3.841 (0.914–16.139) 0.0661
Female 1
Age
≤ 60 0 – 0.629 0.655 0.922 0.533 (0.148–1.926) 0.3369
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